Vaccinex
OTC: VCNXRochester, US · Delaware corporation · 29 employees on LinkedIn · 1 known investors
Find your way into Vaccinex
50 people in our graph share verified history with the Vaccinex team — schools, employers, funds. One of them is your warm intro.
Maia Hightowerunlockedknows Elizabeth Evans · together at University of Rochester School of Medicine and Dentistry (overlapped)
knows the team · via Carestream
×5knows the team · via Rochester Institute of Technology
knows the team · via University of Rochester School of Medicine and Dentistry
knows the team · via Vaccinex
×3knows the team · via St. John Fisher College
Vaccinex is a clinical-stage biotechnology company developing pepinemab (VX15/2503), a humanized monoclonal antibody that blocks SEMA4D signaling, in trials for neurological disorders such as Huntington's and Alzheimer's disease and for solid tumors including breast cancer, melanoma, non-small cell lung cancer and head and neck cancer. It also offers a fusion protein and ActivMab antibody discovery technology for incorporating membrane proteins such as GPCRs and ion channels into poxviruses for antibody selection.
Founders & leadership
MZ
Maurice Zauderer, Ph.D.Co-founder
MZ
Maurice ZaudererinCo-founder
EE
Elizabeth EvansinChief Operating OfficerElizabeth Evans is Chief Operating Officer and Senior Vice President of Discovery and Translational Medicine at Vaccinex, where she has led antibody and antigen discovery, translational research, and clinical development of monoclonal antibodies and biologics since the company's inception, with focus on immunotherapy and neurological diseases including Huntington's and Alzheimer's.
ES
Ernest S. Smith Ph.D.Executive
JS
Jill SanchezinChief Financial Officer
ES
Ernest S. SmithinExecutiveErnest S. Smith is Senior Vice President, Research and Chief Scientific Officer at Vaccinex, a Rochester-based biotechnology company developing therapeutic monoclonal antibodies. He joined the company at its founding in 1997 and contributed to the development of the company's cDNA library and antibody discovery technologies.
RW
Raymond WatkinsinExecutive
SE
Scott E. RoyerinExecutiveScott E. Royer is an Executive Officer at Vaccinex, a clinical-stage biotechnology company developing monoclonal antibodies and antibody discovery technology for neurological and oncological indications. He brings 22 years of experience in financial leadership, corporate finance, treasury, and operations across multiple business domains.
EE
Elizabeth E. EvansinChief Operating OfficerElizabeth E. Evans is Chief Operating Officer and Senior Vice President, Discovery and Translational Medicine at Vaccinex, where she has led antigen and antibody discovery, translational research, and clinical development of monoclonal antibodies and biologic therapeutics since the company's inception.
Board
JB
Jacob B. FriebergBoard director
AD
Albert D. FriedbergBoard director
CB
Chrystyna Bedrij StecykBoard director
Investors · 1
Funding
SEC filings, press & company announcements$104.5M disclosed across 10 of 11 rounds · 2017–2025
- $60MraisedDec 2025 · 3 sourcesSource ↗
▶$200.2KraisedSep 2024 · 8 investors · PharmaceuticalsRule 506(b)
▶$200.2KraisedSep 2024 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jacob B. FriebergDirector
- Gerald E. Van StrydonckDirector
- Albert D. FriedbergDirector
- Maurice Zauderer, Ph.D.Director, Executive Officer
- Elizabeth EvansExecutive Officer
- Barbara YanniDirector
- Ernest S. Smith Ph.D.Executive Officer
- Jill SanchezExecutive Officer
- Bala S. Manian Ph.D.Director
- Offering amount
- $9.2M
- Amount sold
- $200.2K
- Sales commissions
- $8.8K
- Placement agents
- Roth Capital Partners, LLC
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MofferedApr 2024 · 4 investors · PharmaceuticalsRule 506(b)
▶$1.5MofferedApr 2024 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Bala S. Manian, Ph.D.Director
- Jacob B. FriebergDirector
- Albert D. FriedbergDirector
- Ernest S. Smith, Ph.D.Executive Officer
- Gerald E. Van StrydonckDirector
- Barbara YanniDirector
- Maurice Zauderer, Ph.D.Director, Executive Officer
- Jill SanchezExecutive Officer
- Chrystyna Bedrij StecykDirector
- Elizabeth EvansExecutive Officer
- Offering amount
- $1.5M
- Finders' fees
- $215K
- Placement agents
- A.G.P./Alliance Global Partners
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.2MraisedApr 2024 · 3 investors · PharmaceuticalsRule 506(b)
▶$1.2MraisedApr 2024 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jill SanchezExecutive Officer
- Maurice Zauderer, Ph.D.Director, Executive Officer
- Barbara YanniDirector
- Bala S. Manian, Ph.D.Director
- Jacob B. FriebergDirector
- Albert D. FriedbergDirector
- Ernest S. Smith, Ph.D.Executive Officer
- Elizabeth EvansExecutive Officer
- Chrystyna Bedrij StecykDirector
- Gerald E. Van StrydonckDirector
- Offering amount
- $2.5M
- Amount sold
- $1.2M
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.8MraisedApr 2024 · 1 investors · PharmaceuticalsRule 506(b)
▶$1.8MraisedApr 2024 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Chrystyna Bedrij StecykDirector
- Elizabeth EvansExecutive Officer
- Jill SanchezExecutive Officer
- Maurice Zauderer, Ph.D.Director, Executive Officer
- Ernest S. Smith, Ph.D.Executive Officer
- Gerald E. Van StrydonckDirector
- Bala S. Manian, Ph.D.Director
- Jacob B. FriebergDirector
- Albert D. FriedbergDirector
- Barbara YanniDirector
- Offering amount
- $3.5M
- Amount sold
- $1.8M
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedSep 2020 · 1 investors · PharmaceuticalsRule 506(b)
▶$2MraisedSep 2020 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gerald E. Van StrydonckDirector
- J. Jeffrey GoaterDirector
- Bala S. ManianDirector
- Chrystyna Bedrij StecykDirector
- Barbara YannniDirector
- Scott E. RoyerExecutive Officer
- Raymond WatkinsExecutive Officer
- Jacob B. FriebergDirector
- Maurice ZaudererExecutive Officer, Director
- Albert D. FriedbergDirector
- Ernest S. SmithExecutive Officer
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8MraisedAug 2020 · 1 investors · PharmaceuticalsRule 506(b)
▶$8MraisedAug 2020 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gerald E. Van StrydonckDirector
- J. Jeffrey GoaterDirector
- Barbara YannniDirector
- Chrystyna Bedrij StecykDirector
- Jacob B. FriebergDirector
- Albert D. FriedbergDirector
- Ernest S. SmithExecutive Officer
- Bala S. ManianDirector
- Maurice ZaudererExecutive Officer, Director
- Raymond WatkinsExecutive Officer
- Scott E. RoyerExecutive Officer
- Offering amount
- $8M
- Amount sold
- $8M
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedJul 2020 · 1 investors · PharmaceuticalsRule 506(b)
▶$4MraisedJul 2020 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ernest S. SmithExecutive Officer
- J. Jeffrey GoaterDirector
- Alejandro M. BerlinDirector
- Bala S. ManianDirector
- Raymond WatkinsExecutive Officer
- Scott E. RoyerExecutive Officer
- Jacob B. FriebergDirector
- Gerald E. Van StrydonckDirector
- Barbara YanniDirector
- Albert D. FriedbergDirector
- Chrystyna Bedrij StecykDirector
- Maurice ZaudererExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.5MraisedFeb 2020 · 5 investors · PharmaceuticalsRule 506(b)
▶$7.5MraisedFeb 2020 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jacob B. FriebergDirector
- Maurice ZaudererExecutive Officer, Director
- Scott E. RoyerExecutive Officer
- Raymond WatkinsExecutive Officer
- Ernest S. SmithExecutive Officer
- Barbara YanniDirector
- J. Jeffrey GoaterDirector
- Bala S. ManianDirector
- Gerald E. Van StrydonckDirector
- Alejandro M. BerlinDirector
- Albert D. FriedbergDirector
- Offering amount
- $7.5M
- Amount sold
- $7.5M
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$137.7Mvaluation at IPOAug 2018 · $12.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 4
by search overlapImvax53 shared keywordsImvax is a clinical-stage biopharmaceutical company developing personalized immunotherapies aimed at treating solid tumors, including glioblastoma. Its platform draws on autologous, cell-based approaches to target cancer.
Bioworld49 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Dynavax NASDAQ: DVAX www.dynavax.com47 shared keywordsDynavax is a commercial-stage biopharmaceutical company that develops and commercializes vaccines against infectious diseases using its adjuvant technology. Its products target immunization and infectious disease prevention.
Vaxcyte40 shared keywordsVaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques. Its pipeline includes pneumococcal conjugate vaccines (VAX-31 and VAX-24) and early-stage candidates targeting Group A Strep and Shigella.
Companies competing with Vaccinex for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Vaccinex do?
- Vaccinex is a clinical-stage biotechnology company developing pepinemab (VX15/2503), a humanized monoclonal antibody that blocks SEMA4D signaling, in trials for neurological disorders such as Huntington's and Alzheimer's disease and for solid tumors including breast cancer, melanoma, non-small cell lung cancer and head and neck cancer. It also offers a fusion protein and ActivMab antibody discovery technology for incorporating membrane proteins such as GPCRs and ion channels into poxviruses for antibody selection.
- Who founded Vaccinex?
- Vaccinex was founded by Maurice Zauderer, Ph.D., Maurice Zauderer.
- Who are Vaccinex's investors?
- Vaccinex's investors include Polaris Partners.
- How much funding has Vaccinex raised?
- Vaccinex has disclosed $104.5M raised across 10 of its 11 known rounds.
- Where is Vaccinex headquartered?
- Vaccinex is headquartered in Rochester, US.